within Pharmacolibrary.Drugs.ATC.L;

model L01XX29
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 18 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0054,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.004,
    k12             = 2.3,
    k21             = 2.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XX29</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Denileukin diftitox is a recombinant fusion protein composed of interleukin-2 and diphtheria toxin fragments. It binds to the high-affinity interleukin-2 (IL-2) receptor, resulting in selective cytotoxicity against malignant cells expressing this receptor. It was previously approved for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), but its use has been discontinued and is not currently approved or marketed.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adults (both sexes) with cutaneous T-cell lymphoma, as peer-reviewed sources don't provide explicit compartmental PK model parameters.</p><h4>References</h4><ol><li><p>Kawai, H, et al., &amp; Tobinai, K (2021). Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. <i>Cancer science</i> 112(6) 2426–2435. DOI:<a href=\"https://doi.org/10.1111/cas.14906\">10.1111/cas.14906</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33792128/\">https://pubmed.ncbi.nlm.nih.gov/33792128</a></p></li><li><p>Ohmachi, K, et al., &amp; Nakanishi, T (2018). E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study. <i>Cancer science</i> 109(3) 794–802. DOI:<a href=\"https://doi.org/10.1111/cas.13513\">10.1111/cas.13513</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29363235/\">https://pubmed.ncbi.nlm.nih.gov/29363235</a></p></li><li><p>LeMaistre, CF, et al., &amp; Nichols, JC (1998). Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. <i>Blood</i> 91(2) 399–405. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9427692/\">https://pubmed.ncbi.nlm.nih.gov/9427692</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XX29;
